These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 16083333)
1. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Correia ML; Haynes WG Expert Opin Emerg Drugs; 2005 Aug; 10(3):643-60. PubMed ID: 16083333 [TBL] [Abstract][Full Text] [Related]
2. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Bays HE Obes Res; 2004 Aug; 12(8):1197-211. PubMed ID: 15340100 [TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
4. [Drug treatment of obesity--current situation and perspectives]. Hainer V Cas Lek Cesk; 2010; 149(11):513-9. PubMed ID: 21391349 [TBL] [Abstract][Full Text] [Related]
5. Emerging pharmacological approaches to the treatment of obesity. Wasan KM; Looije NA J Pharm Pharm Sci; 2005 Aug; 8(2):259-71. PubMed ID: 16124937 [TBL] [Abstract][Full Text] [Related]
6. New drug targets for the treatment of obesity. Powell AG; Apovian CM; Aronne LJ Clin Pharmacol Ther; 2011 Jul; 90(1):40-51. PubMed ID: 21654742 [TBL] [Abstract][Full Text] [Related]
7. The obesity epidemic: current and future pharmacological treatments. Hofbauer KG; Nicholson JR; Boss O Annu Rev Pharmacol Toxicol; 2007; 47():565-92. PubMed ID: 17002599 [TBL] [Abstract][Full Text] [Related]
8. Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Jackson VM; Price DA; Carpino PA Expert Opin Investig Drugs; 2014 Aug; 23(8):1055-66. PubMed ID: 25000213 [TBL] [Abstract][Full Text] [Related]
9. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes. Bjenning C; Al-Shamma H; Thomsen W; Leonard J; Behan D Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426 [TBL] [Abstract][Full Text] [Related]
10. The promise of ghrelin antagonism in obesity treatment. Helmling S; Jarosch F; Klussmann S Drug News Perspect; 2006; 19(1):13-20. PubMed ID: 16550252 [TBL] [Abstract][Full Text] [Related]
11. Addressing the unmet medical need for safe and effective weight loss therapies. Arbeeny CM Obes Res; 2004 Aug; 12(8):1191-6. PubMed ID: 15340099 [TBL] [Abstract][Full Text] [Related]
12. Companies throw their weight behind new antiobesity drugs. Cahoon L Nat Med; 2010 Feb; 16(2):136. PubMed ID: 20134442 [No Abstract] [Full Text] [Related]
14. Pharmaceutical approaches to the treatment of obesity. Jandacek RJ; Woods SC Drug Discov Today; 2004 Oct; 9(20):874-80. PubMed ID: 15475320 [TBL] [Abstract][Full Text] [Related]
15. Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns. Elangbam CS Vet Pathol; 2009 Jan; 46(1):10-24. PubMed ID: 19112110 [TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for the treatment of myelodysplastic syndrome. Nivatpumin PJ; Gore SD Expert Opin Emerg Drugs; 2005 Aug; 10(3):569-90. PubMed ID: 16083330 [TBL] [Abstract][Full Text] [Related]
17. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Heal DJ; Gosden J; Smith SL Br J Clin Pharmacol; 2009 Dec; 68(6):861-74. PubMed ID: 20002080 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological treatments for obesity. McLoughlin C Prof Nurse; 2005 Apr; 20(8):50-1. PubMed ID: 15819320 [TBL] [Abstract][Full Text] [Related]
19. Challenges in the discovery and development of new agents for the treatment of obesity. Staten MA Clin Pharmacol Ther; 2007 May; 81(5):753-5. PubMed ID: 17377527 [TBL] [Abstract][Full Text] [Related]
20. FGF21: a novel prospect for the treatment of metabolic diseases. Kharitonenkov A; Shanafelt AB Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]